HR and breast carcinoma: The success rates according to breast cancer subtype were 3.6% for HR+/HER2−, 21.4% for HR+/HER2+, 21.9% for HR−/HER2+, and 22.5% for triple-negative breast cancer (TNBC) (Figure 1B).